Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039701074> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2039701074 endingPage "2" @default.
- W2039701074 startingPage "2" @default.
- W2039701074 abstract "Bisphosphonates (BPs) were designed for the prevention of skeletal-related events secondary to bone metastases. The purpose of this study was to show that zoledronic acid (ZA) directly eradicates highly tumorigenic and potentially metastatic cancer cells.Human prostate and breast highly tumorigenic (PC3, MCF 7) and low- or non-tumorigenic (LNCaP, MCF 10a) cell lines, respectively, were exposed to different concentrations of ZA (0-10 μM). Reverse transcriptase double quantitative polymerase chain reaction was used for quantitative gene expression analysis. Apoptosis and cell proliferation were determined using microscopic observation and MTS assays. Western blot was used to confirm the translational effects of apoptotic genes on protein expression.Human prostate and breast highly tumorigenic (PC3, MCF 7) and low- or non-tumorigenic (LNCaP, MCF 10a) cell lines, respectively, showed multiple genes demonstrating differential expressions, including TRAF, TRADD, BCL2, CASPASES and IAP families. Increasing ZA concentrations showed a greater concentration-time response on cell proliferation and apoptosis in the highly tumorigenic cells. These results were confirmed by both reversing and enhancing the effect of ZA on cell proliferation with caspase 3, 7 or survivin siRNA, respectively. Pro-apoptotic proteins bax and caspase 2, 3, 7 and 9 were up-regulated, while the anti-apoptotic proteins bcl2, birc3 and survivin were down-regulated only in the highly tumorigenic cells.This explains the ability of ZA to inhibit bony metastasis in highly tumorigenic cells compared with the low- or non-tumorigenic cells through a significant decrease in cell proliferation and increase in apoptosis through gene-regulated and translational-mediated down-regulation of survivin coupled with the inhibition of caspase 3 or 7. This has significant implications toward understanding the pharmacophysiology of BPs in metastasis and supports the clinically observed effect of BPs when administered adjunctively with anticancer drugs such as cyclophosphamide/methotrexate/5-fluorouracil, epirubicin in combination with cyclophosphamide or docetaxel, and doxorubicin." @default.
- W2039701074 created "2016-06-24" @default.
- W2039701074 creator A5011531365 @default.
- W2039701074 creator A5013152614 @default.
- W2039701074 creator A5017285893 @default.
- W2039701074 creator A5018636858 @default.
- W2039701074 creator A5065926670 @default.
- W2039701074 creator A5080733133 @default.
- W2039701074 date "2011-01-01" @default.
- W2039701074 modified "2023-10-16" @default.
- W2039701074 title "Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers" @default.
- W2039701074 cites W2122919091 @default.
- W2039701074 cites W2167494923 @default.
- W2039701074 doi "https://doi.org/10.4103/1477-3163.75723" @default.
- W2039701074 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3030761" @default.
- W2039701074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21297922" @default.
- W2039701074 hasPublicationYear "2011" @default.
- W2039701074 type Work @default.
- W2039701074 sameAs 2039701074 @default.
- W2039701074 citedByCount "45" @default.
- W2039701074 countsByYear W20397010742012 @default.
- W2039701074 countsByYear W20397010742013 @default.
- W2039701074 countsByYear W20397010742014 @default.
- W2039701074 countsByYear W20397010742015 @default.
- W2039701074 countsByYear W20397010742016 @default.
- W2039701074 countsByYear W20397010742017 @default.
- W2039701074 countsByYear W20397010742018 @default.
- W2039701074 countsByYear W20397010742019 @default.
- W2039701074 countsByYear W20397010742020 @default.
- W2039701074 countsByYear W20397010742022 @default.
- W2039701074 crossrefType "journal-article" @default.
- W2039701074 hasAuthorship W2039701074A5011531365 @default.
- W2039701074 hasAuthorship W2039701074A5013152614 @default.
- W2039701074 hasAuthorship W2039701074A5017285893 @default.
- W2039701074 hasAuthorship W2039701074A5018636858 @default.
- W2039701074 hasAuthorship W2039701074A5065926670 @default.
- W2039701074 hasAuthorship W2039701074A5080733133 @default.
- W2039701074 hasBestOaLocation W20397010741 @default.
- W2039701074 hasConcept C121608353 @default.
- W2039701074 hasConcept C126322002 @default.
- W2039701074 hasConcept C1491633281 @default.
- W2039701074 hasConcept C190283241 @default.
- W2039701074 hasConcept C2775975398 @default.
- W2039701074 hasConcept C2779723316 @default.
- W2039701074 hasConcept C2780192828 @default.
- W2039701074 hasConcept C502942594 @default.
- W2039701074 hasConcept C54355233 @default.
- W2039701074 hasConcept C55493867 @default.
- W2039701074 hasConcept C555283112 @default.
- W2039701074 hasConcept C62112901 @default.
- W2039701074 hasConcept C71924100 @default.
- W2039701074 hasConcept C81885089 @default.
- W2039701074 hasConcept C86803240 @default.
- W2039701074 hasConceptScore W2039701074C121608353 @default.
- W2039701074 hasConceptScore W2039701074C126322002 @default.
- W2039701074 hasConceptScore W2039701074C1491633281 @default.
- W2039701074 hasConceptScore W2039701074C190283241 @default.
- W2039701074 hasConceptScore W2039701074C2775975398 @default.
- W2039701074 hasConceptScore W2039701074C2779723316 @default.
- W2039701074 hasConceptScore W2039701074C2780192828 @default.
- W2039701074 hasConceptScore W2039701074C502942594 @default.
- W2039701074 hasConceptScore W2039701074C54355233 @default.
- W2039701074 hasConceptScore W2039701074C55493867 @default.
- W2039701074 hasConceptScore W2039701074C555283112 @default.
- W2039701074 hasConceptScore W2039701074C62112901 @default.
- W2039701074 hasConceptScore W2039701074C71924100 @default.
- W2039701074 hasConceptScore W2039701074C81885089 @default.
- W2039701074 hasConceptScore W2039701074C86803240 @default.
- W2039701074 hasIssue "1" @default.
- W2039701074 hasLocation W20397010741 @default.
- W2039701074 hasLocation W20397010742 @default.
- W2039701074 hasLocation W20397010743 @default.
- W2039701074 hasLocation W20397010744 @default.
- W2039701074 hasOpenAccess W2039701074 @default.
- W2039701074 hasPrimaryLocation W20397010741 @default.
- W2039701074 hasRelatedWork W2010072924 @default.
- W2039701074 hasRelatedWork W2039701074 @default.
- W2039701074 hasRelatedWork W2062995999 @default.
- W2039701074 hasRelatedWork W2102856042 @default.
- W2039701074 hasRelatedWork W2185175380 @default.
- W2039701074 hasRelatedWork W2355259601 @default.
- W2039701074 hasRelatedWork W2361455118 @default.
- W2039701074 hasRelatedWork W2383691845 @default.
- W2039701074 hasRelatedWork W2394007071 @default.
- W2039701074 hasRelatedWork W2738575927 @default.
- W2039701074 hasVolume "10" @default.
- W2039701074 isParatext "false" @default.
- W2039701074 isRetracted "false" @default.
- W2039701074 magId "2039701074" @default.
- W2039701074 workType "article" @default.